vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and GCL Global Holdings Ltd (GCL). Click either name above to swap in a different company.

GCL Global Holdings Ltd is the larger business by last-quarter revenue ($98.7M vs $77.6M, roughly 1.3× Bioceres Crop Solutions Corp.). GCL Global Holdings Ltd runs the higher net margin — -5.2% vs -9.6%, a 4.4% gap on every dollar of revenue.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.

BIOX vs GCL — Head-to-Head

Bigger by revenue
GCL
GCL
1.3× larger
GCL
$98.7M
$77.6M
BIOX
Higher net margin
GCL
GCL
4.4% more per $
GCL
-5.2%
-9.6%
BIOX

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
BIOX
BIOX
GCL
GCL
Revenue
$77.6M
$98.7M
Net Profit
$-7.4M
$-5.1M
Gross Margin
46.8%
11.0%
Operating Margin
9.3%
-6.7%
Net Margin
-9.6%
-5.2%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
GCL
GCL
Q3 25
$77.6M
$98.7M
Q2 25
$142.1M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
$36.1M
Q1 24
$84.0M
Q4 23
$140.2M
Q3 23
$116.6M
Net Profit
BIOX
BIOX
GCL
GCL
Q3 25
$-7.4M
$-5.1M
Q2 25
$5.6M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
$-1.9M
Q1 24
$9.8M
Q4 23
$1.2M
Q3 23
$-2.7M
Gross Margin
BIOX
BIOX
GCL
GCL
Q3 25
46.8%
11.0%
Q2 25
15.0%
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
16.2%
Q1 24
50.8%
Q4 23
36.7%
Q3 23
38.6%
Operating Margin
BIOX
BIOX
GCL
GCL
Q3 25
9.3%
-6.7%
Q2 25
2.3%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
-5.6%
Q1 24
15.7%
Q4 23
12.0%
Q3 23
4.5%
Net Margin
BIOX
BIOX
GCL
GCL
Q3 25
-9.6%
-5.2%
Q2 25
3.9%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
-5.2%
Q1 24
11.6%
Q4 23
0.9%
Q3 23
-2.3%
EPS (diluted)
BIOX
BIOX
GCL
GCL
Q3 25
$-0.12
$-0.04
Q2 25
$0.05
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q1 24
$0.14
Q4 23
$0.00
Q3 23
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
GCL
GCL
Cash + ST InvestmentsLiquidity on hand
$15.5M
$16.6M
Total DebtLower is stronger
$52.0M
Stockholders' EquityBook value
$288.3M
$33.1M
Total Assets
$734.9M
$159.9M
Debt / EquityLower = less leverage
1.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
GCL
GCL
Q3 25
$15.5M
$16.6M
Q2 25
$18.2M
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
$2.7M
Q1 24
$16.4M
Q4 23
$24.4M
Q3 23
$28.4M
Total Debt
BIOX
BIOX
GCL
GCL
Q3 25
$52.0M
Q2 25
$11.9M
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Stockholders' Equity
BIOX
BIOX
GCL
GCL
Q3 25
$288.3M
$33.1M
Q2 25
$35.9M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
$15.9M
Q1 24
$348.5M
Q4 23
$335.3M
Q3 23
$332.6M
Total Assets
BIOX
BIOX
GCL
GCL
Q3 25
$734.9M
$159.9M
Q2 25
$101.6M
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
$49.6M
Q1 24
$836.1M
Q4 23
$819.5M
Q3 23
$819.7M
Debt / Equity
BIOX
BIOX
GCL
GCL
Q3 25
1.57×
Q2 25
0.33×
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
GCL
GCL
Operating Cash FlowLast quarter
$14.4M
$-4.8M
Free Cash FlowOCF − Capex
$-5.2M
FCF MarginFCF / Revenue
-5.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
GCL
GCL
Q3 25
$14.4M
$-4.8M
Q2 25
$-10.3M
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
$6.1M
Q1 24
$-17.4M
Q4 23
$21.1M
Q3 23
$14.7M
Free Cash Flow
BIOX
BIOX
GCL
GCL
Q3 25
$-5.2M
Q2 25
$-10.5M
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
FCF Margin
BIOX
BIOX
GCL
GCL
Q3 25
-5.3%
Q2 25
-7.4%
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Capex Intensity
BIOX
BIOX
GCL
GCL
Q3 25
0.4%
Q2 25
0.1%
Q1 25
Q4 24
Q3 24
Q1 24
Q4 23
Q3 23
Cash Conversion
BIOX
BIOX
GCL
GCL
Q3 25
Q2 25
-1.84×
Q1 25
Q4 24
-8.85×
Q3 24
Q1 24
-1.78×
Q4 23
17.05×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons